[MRSH] Marsh: Can Broking Growth Hold at 4% as Insurance Rates Fall 6%?

Marsh (NYSE: MRSH) is one of the world's largest insurance broking and risk advisory groups, founded in Chicago in 1871, headquartered today in New York, and arranging insurance, reinsurance, employee benefits and strategy consulting for companies, insurers and governments across 130 countries [1]. The company is scheduled to report FY2026 Q3 (three months ended September 30, 2026) on 2026-10-15 [2]. The most recent disclosed quarter is the second quarter of 2026: revenue of $7.404 billion, up 6% on a reported basis and 5% on an underlying basis that strips out acquisitions and currency, an adjusted operating margin of 29.3%, and adjusted earnings per share of $2.96, up 9% year over year [3][4]. On that call, management set out several expectations that land directly in the third quarter: underlying growth at Marsh Management Consulting in the mid-to-high single digits, fiduciary interest income of roughly $95 million, adjusted corporate expense of about $75 million, interest expense similar to the second quarter's $250 million, and a deliberate warning that margin expansion will be larger in the fourth quarter than in the third [3]. On the sell-side, MarketBeat's aggregated consensus for third-quarter adjusted earnings per share sits at $1.98 in a range of $1.95 to $2.05, a figure that cannot be ranked directly against the $2.96 reported in the second quarter because the third quarter is seasonally the group's smallest [5].

Three things are worth watching in this set of results. First is the quality of growth in the core broking business during a soft market: the company's own composite rate index fell 6% year over year in the second quarter, deeper than the 5% decline in the first, yet Marsh Risk, the largest broking unit, still delivered 4% underlying growth, with the US and Canada recovering from 3% in the first quarter to 4%; whether that level holds in the third quarter decides whether the growth comes from winning new business or from the steadier pricing of the middle market [3]. Second is whether the slowdown at Mercer Health is a step down rather than noise: health underlying growth fell from 6% in the first quarter to 3% in the second, and management put that down to strong new business with only average retention, so a return to 5% and a reading stuck below 4% point to two entirely different conclusions [3][6]. Third is whether margin expansion appears in the third quarter at all: the company has steered the expansion toward the fourth quarter, while the third has to absorb both the year-over-year decline in fiduciary interest income and a rise in adjusted corporate expense from $67 million to about $75 million, which makes it the cleanest test yet of the Thrive cost programme [3].

Company Background and Business Structure

The boundaries of Marsh's business today are drawn by a brand consolidation that is still in progress and by four distinct ways of charging clients. On January 14, 2026, the company changed its group brand from Marsh McLennan to Marsh, renamed the insurance broking business from Marsh to Marsh Risk, and renamed the management consulting business from Oliver Wyman Group to Marsh Management Consulting, while Mercer and Guy Carpenter kept their existing brands through a transition period; the company stated explicitly that the renaming changes neither how it operates nor how it reports segments [1]. By the second-quarter 2026 call, management said the response to the new brand had been strongly positive and therefore pulled forward the folding of Guy Carpenter and Mercer into Marsh to September [3]. Names aside, the company runs four kinds of business: arranging insurance and advising on risk for corporates, arranging reinsurance and connecting insurers to alternative capital, advising employers on health and retirement benefits while managing pension and investment assets on their behalf, and providing strategy and transformation consulting to companies and governments [1].

Risk and Insurance Services (RIS) is the bulk of group revenue and also the most geographically concentrated piece. In FY2025 the segment generated $17.265 billion, or 64% of the group's $26.981 billion, of which Marsh Risk contributed $14.366 billion (US and Canada $8.523 billion, international $5.843 billion, split between EMEA at $3.812 billion, Asia Pacific at $1.460 billion and Latin America at $571 million), Guy Carpenter contributed $2.496 billion, and fiduciary interest income, which carries almost no matching cost, added $403 million [7]. That structure carries a practical implication: the US and Canada alone account for roughly a third of group revenue, so pricing and new-business momentum in the North American commercial insurance market matter far more to the group's overall growth rate than any other single market [7].

The Consulting segment supplies the other third or so of revenue, but with a visibly different margin structure. FY2025 consulting revenue was $9.794 billion, 36% of the group, made up of Mercer at $6.190 billion (wealth $2.819 billion, health $2.284 billion, career $1.087 billion) and Marsh Management Consulting at $3.604 billion [7]. By the second quarter of 2026, the adjusted operating margin was 35.3% in RIS against 20.5% in consulting, with the group at 29.3%, which means any tilt in the revenue mix toward consulting dilutes the group margin on its own [3]. Clients pay through commissions calculated on premium, project fees, basis-point fees on assets under management and success fees, while the cost base is dominated by people, and the company is centralising operations and technology through an organisation called Business Client Services, or BCS [1].

Financial History and Current Position

Marsh has grown revenue every year for the past five, but the source of that growth changed in the most recent year. Revenue rose from $19.820 billion in FY2021 to $22.736 billion in FY2023, $24.458 billion in FY2024 and $26.981 billion in FY2025; of the 10% increase in FY2025, six percentage points came from acquisitions, chiefly McGriff, leaving only 4% on an underlying basis, split 4% in RIS and 5% in consulting [1][7]. Operating income over the same period climbed from $5.282 billion in FY2023 to $5.817 billion in FY2024 and $6.223 billion in FY2025, with FY2025 net income of $4.160 billion and diluted earnings per share of $8.43; operating expenses that year reached $20.8 billion, up 11% and faster than revenue, driven mainly by compensation and consolidated acquisitions, and including $222 million of restructuring charges of which $150 million related to the Thrive programme launched in the third quarter of 2025 [1].

Cash generation and the uses of that cash are equally clear on an annual basis. FY2025 operating cash flow was $5.292 billion against capital expenditure of only $291 million, leaving free cash flow of $5.001 billion; the company repurchased $2.012 billion of stock, paid $1.699 billion of dividends and spent $652 million net on acquisitions [1]. The year-end balance sheet carried $21.449 billion of total debt, $2.687 billion of cash, $24.337 billion of goodwill and $15.100 billion of shareholders' equity, and goodwill exceeding equity is itself a record of how long this business has expanded through acquisition [1].

Into 2026, the two reported quarters exposed different problems. First-quarter revenue was $7.597 billion, up 8% on a reported basis and 4% underlying, but GAAP operating income fell 12% because of a $425 million charge tied to Greensill-related litigation, leaving GAAP earnings per share of $2.36 against $3.29 adjusted, up 8%, with the adjusted operating margin flat year over year at 31.8% [6][8]. Second-quarter revenue was $7.404 billion, up 6% on a reported basis and 5% underlying, with operating income of $1.899 billion, adjusted operating income of $2.2 billion, up 5%, an adjusted operating margin of 29.3%, GAAP earnings per share of $2.63 and $2.96 adjusted; for the first half, adjusted earnings per share reached $6.25, up 8%, on an adjusted operating margin of 30.5% [3][4][9]. Total debt at the end of the second quarter was $22.382 billion against $1.700 billion of cash, the company repurchased $1.5 billion and paid $878 million of dividends in the first half, raised its full-year capital deployment plan from about $5 billion to about $5.5 billion, and lifted the quarterly dividend by 10% in July, the seventeenth consecutive annual increase [3][9]. The clearest headwind right now is fiduciary interest income, which fell from $497 million in FY2024 to $403 million in FY2025 and came in at $88 million in the second quarter of 2026, $11 million lower than a year earlier [3][7].

Operating Model

Revenue arrives through three independent pricing mechanisms, each sensitive to something different: price, scale and interest rates. The first is risk and insurance services, where Marsh Risk arranges insurance for corporates and charges commission on premium or fees on projects, and Guy Carpenter arranges reinsurance for insurers and connects them to catastrophe bonds and alternative capital, charging commission on ceded premium; revenue on this line is roughly premium written multiplied by commission rate, with price set by market rates and volume set by new business, client retention and middle-market acquisitions, totalling $16.862 billion in FY2025 [1][7]. The second is consulting, where Mercer's health and career businesses charge by covered lives and project, its wealth business charges basis points on assets under management, and Marsh Management Consulting bills by project including success fees, together producing $9.794 billion in FY2025 [7]. The third is fiduciary interest income, earned on client premium the company holds while collecting and remitting it, which moves directly with short-term rates and fell to $403 million in FY2025 from $497 million in FY2024, meaning that falling rates cut profit directly with no offsetting cost relief [7].

The direction of the margin is set by three forces pushing up and three pushing down. On the way up are operating leverage from revenue growth, roughly $400 million of annualised savings from the Thrive programme through process centralisation, moving work to lower-cost locations and artificial-intelligence automation, and the business mix itself, since the RIS adjusted margin of 35.3% in the second quarter of 2026 sits well above consulting's 20.5% [3][10]. On the way down are the shrinking, almost cost-free fiduciary interest income during a rate-cutting cycle, reinvestment in producers and brand to support growth, and corporate expense at the group level [3]. One measurement point needs stating plainly: the company classifies restructuring, acquisition integration, changes in contingent consideration and amortisation of identified intangibles as noteworthy items and excludes them from adjusted profit, so Thrive's own costs never depress the adjusted margin, and whether its savings are actually landing can only be inferred indirectly from the year-over-year move in the adjusted operating margin [1][10].

Cash flow is intensely seasonal, and the uses of cash follow a fixed order of priority. The first quarter is a net outflow because annual incentives are paid then, with first-quarter 2026 operating cash flow at negative $688 million, and the following three quarters make it back, producing FY2025 operating cash flow of $5.292 billion, capital expenditure of $291 million and free cash flow of $5.001 billion [1][8]. Cash goes first to a dividend that rises every year, $1.699 billion paid in FY2025 and raised another 10% in July 2026 for a seventeenth consecutive increase; then to acquisitions, where the company says it prefers smaller, continuous deals and spent $652 million net in FY2025; and only the remainder goes to buybacks, which were $2.012 billion in FY2025 [1][3]. For 2026 the company raised the combined plan for those three uses from about $5 billion to about $5.5 billion and stated that the eventual size of the buyback depends on the acquisition pipeline; on leverage, total debt at the end of the second quarter of 2026 was $22.382 billion against $1.700 billion of cash [3][9].

Industry and Competitive Position

Marsh sits at the top of both the commercial insurance broking and the reinsurance broking markets, and its advantage comes mainly from scale rather than from any single product. The company says it leads in most of the markets where it operates, Guy Carpenter holds the largest property catastrophe reinsurance portfolio in the world, and Mercer is the largest outsourced chief investment officer (OCIO) platform, meaning an outside manager runs the whole portfolio, with roughly $16 trillion of assets under advisement and $846 billion of assets under management at the end of the second quarter of 2026 [1][3]. That scale shows up in two places: the proprietary accumulation of risk, health, career and investment data, on the basis of which the company argues it will benefit from artificial intelligence rather than be routed around as an intermediary; and the capacity to invest, with management saying publicly that smaller brokers unable to fund technology will become acquisition targets [1].

The same scale advantage has not translated into the fastest growth in the peer group, and that is the key limitation in reading the company's current position. Its direct comparables are Aon, Arthur J. Gallagher, Brown & Brown and WTW [1]. Anthony Lee of StockStory placed Marsh's second-quarter revenue of $7.40 billion, up 6.2% year over year, alongside four other insurance brokers on August 26, 2026, and concluded that although Marsh came in 1.8% ahead of market expectations, its revenue growth was the slowest in that group [11]. The comparison has its own boundaries: the companies in that group differ greatly in size, and smaller peers find it easier to post higher percentage growth, so what it offers is a relative coordinate rather than a direct conclusion about operating capability.

Core Debates

With commercial insurance rates falling for a fifth straight quarter, can Marsh Risk keep its underlying growth at 4% on new business and producer hiring rather than price?

Marsh Risk alone accounted for 53.2% of group revenue in FY2025, so how it performs in a soft market is very nearly the group's underlying growth rate itself [7]. Revenue on this line is priced off premium or project, so falling prices subtract directly from what the same set of renewing clients contributes, which makes the real question whether Marsh's growth was bought, handed to it by price, or earned. In the second quarter of 2026 the company's own composite rate index fell 6% year over year, deeper than the 5% decline in the first quarter, with the United States down 2% and global property down 12%; in that same quarter Marsh Risk still grew 4% on an underlying basis on revenue of $4.071 billion, with the US and Canada recovering from 3% in the first quarter to 4% and international holding at 5% (EMEA 5%, Asia Pacific 5%, Latin America 8%) [3][7][9].

Management attributed the recovery in the US and Canada to strong new business and to the experienced broking teams hired in the United States during the first half, adding that the hiring trend would continue into the second half [3]. An alternative reading is equally consistent with the evidence: a meaningful share of that 4% may come from the middle-market agency business (MMA), since the company itself says middle-market pricing is steadier across the cycle and the rate index excludes that book; if so, the resilience comes from business mix rather than from an improved ability to win new accounts, and it would fall away once middle-market pricing softens too [3]. The transmission path is not in dispute: commercial insurance rates set the premium base on every renewing policy, commissions and advisory fees are charged on premium or project, and falling rates shrink renewal revenue from the same clients, so holding underlying growth requires new business, retention and middle-market acquisitions to supply the volume and mix, which shows up first in Marsh Risk revenue and then aggregates into RIS segment revenue and operating income [1].

The dividing line between those two readings runs through the US and Canada number. What to watch is whether third-quarter underlying growth at Marsh Risk is still 4% and whether the US and Canada hold at 4%, whether the composite rate index keeps deepening or begins to narrow and whether the US reading drops below negative 2%, whether the company still attributes growth in the US and Canada to new business and producers rather than to acquisitions or middle-market pricing, and whether the gap between RIS segment underlying growth, which was 3% in the second quarter, and Marsh Risk's 4% widens further because of Guy Carpenter and fiduciary interest income [3]. The observations that would falsify the current reading are specific as well: if rate declines deepen while growth does not move at all, acquisitions and middle-market mix are more likely holding up the number than any improvement in new business capture; the company does not disclose net producer additions or client retention, so evidence that hiring is working can only be inferred from the growth rate; and because the third quarter is seasonally the smallest, a sequential decline in absolute revenue proves nothing [3][7].

Mercer Health's underlying growth fell from 6% to 3% in one quarter; is that noise, or a step down that Wealth now has to cover?

Mercer accounted for 22.9% of group revenue in FY2025, with health and wealth its two largest lines, so the trajectory here determines the quality of growth in the consulting segment [7]. Health growth had held above 5% for years, and the 3% posted in the second quarter is the first clear stall in a long time; if it is a step down, Mercer's overall growth becomes a long-term dependency on wealth, and wealth's 8% in the second quarter was built on assets under management that rose 26% year over year, growth the company itself concedes came from both new business and capital markets [3]. Put differently, this debate decides how much of Mercer's growth has been borrowed from market conditions.

Mercer's second-quarter 2026 revenue was $1.598 billion, up 5% underlying, with health at 3%, wealth at 8% and career at 2%, and health revenue of $611 million in the quarter; the corresponding first-quarter figures were health 6%, wealth 5% and career negative 2% [3][6][9]. Management explained that new business in health was strong while retention was merely average, warned explicitly against extrapolating from a single quarter, argued that the 5% posted for the first half better represents underlying growth, and described medical inflation as a source of pressure on employers [3]. An equally consistent alternative is that weaker retention is itself structural: when medical costs are rising fast, employers switch advisers or put benefits broking out to tender more readily, in which case merely average retention persists rather than reverting to its former level. On the wealth side, the 8% in the second quarter was the best since the company began reporting on this basis in 2016, with period-end assets under management of $846 billion, up 16% sequentially and 26% year over year, and the company has not broken out how much of that came from capital markets [3].

Third-quarter health growth can separate the two readings: a return to 5% supports the company's account, while staying below 4% supports the structural one [3]. Beyond that, watch whether the company still explains health with average retention and strong new business or shifts to acknowledging sustained retention pressure; whether period-end assets under management keep rising sequentially and whether the company attributes that to new mandates rather than markets; and whether AltamarCAM, the private-markets asset manager with roughly €20 billion under management that has been announced but still awaits regulatory approval, closes in the second half as planned and enters the assets-under-management figure [3][6]. The evidential boundaries of this debate are just as clear: health and wealth growth are disclosed only qualitatively by quarter and the company gives no retention rate, so weakening retention can only be inferred from the growth rate; assets under management move with both markets and acquisitions, so a rise does not mean business capture improved; and single-quarter growth is volatile in any case, with the company having explicitly argued against extrapolating from one quarter [3]. In transmission terms, health charges by covered lives and advisory project, with retention setting the installed base and new global benefits management mandates setting the increment, while wealth's investment revenue charges basis points on assets under management, and the two lines combine into Mercer revenue and then, with management consulting, into consulting segment revenue and operating income [1][7].

Marsh Management Consulting just posted its fastest quarter in over two years at 13% underlying growth, yet guided Q3 to mid-to-high single digits; where does it actually land?

Management consulting is only 13.4% of FY2025 group revenue, but it was the main force lifting group underlying growth from 4% to 5% in the second quarter, and it is the one place where the company frames artificial intelligence as a revenue opportunity rather than merely a source of cost savings [3][7]. It is also the only business in the group with a quantified guide for the next quarter, which makes the third quarter the most direct test available of the claim that artificial-intelligence demand is turning into revenue [3].

Management consulting revenue in the second quarter of 2026 was $1.004 billion, up 15% on a reported basis and 13% underlying, which the company called its fastest quarter in more than two years [3][9]. The head of the business described growth as fairly broad-based: every region grew, Europe and Asia were strongest, and industry demand concentrated in energy, insurance, telecoms and transportation; within service lines the fastest-growing by some distance was Quotient, the company's artificial-intelligence strategic advisory team, followed by efficiency work, pre- and post-merger diligence and integration, and private equity and capital deployment work [3]. On the same call the company guided the third quarter down to mid-to-high single digits, explaining that sales slowed in the Middle East during the second quarter and would affect the second half, while the project backlog remained healthy [3].

The guide itself supports a second reading: the 13% may contain a large one-off component such as success fees and concentrated delivery, so that the real quarterly run rate was always in the single digits; on that view, landing between 6% and 9% in the third quarter would be consistent with the guide without implying that artificial-intelligence demand has weakened [3]. Separating the two means watching whether the company still ranks Quotient first for growth, whether the consulting segment's adjusted operating margin of 20.5% in the second quarter expands year over year, and whether the impact of the Middle East slowdown on the second half is quantified by the company or extended to other regions [3]. The largest limitation here is verifiability: the company does not disclose artificial-intelligence revenue separately, so that demand can only be confirmed through management's qualitative ranking; project revenue includes success fees, so one strong quarter is not necessarily durable; and the guide is a directional range rather than a specific number, which leaves considerable room for interpretation if the result lands at the edge of that range [3]. The chain runs from consulting billed by project, where sales convert first into backlog and then into revenue recognised as delivery progresses, so a regional sales slowdown depresses revenue with roughly a one-quarter lag before landing in consulting segment revenue and adjusted operating margin [1].

Marsh has promised another year of margin expansion but steered it toward the fourth quarter; does the third quarter show expansion at all?

Marsh has expanded its operating margin for eighteen consecutive years, and management said explicitly on the first-quarter 2026 call that it intends to make this year the nineteenth [6]. The difficulty this year is that two almost cost-free revenue streams are shrinking: fiduciary interest income already fell from $497 million to $403 million in FY2025 and the company has guided the third quarter to roughly $95 million, while adjusted corporate expense at group level is set to rise from $67 million in the second quarter to about $75 million [3][7]. That means third-quarter margin expansion has to be earned entirely from the cost-structure improvement delivered by Thrive and BCS, which makes it the cleanest quarter for judging what that cost programme is worth.

Thrive began in the third quarter of 2025, runs for three years, and the company expects roughly $500 million of charges to produce roughly $400 million of annualised savings, with charges and savings spread fairly evenly across the programme [3][10]. By June 30, 2026, however, cumulative restructuring charges tied to the programme had already reached $239 million, which means nearly half the budget was consumed in four quarters, noticeably front-loaded relative to an even spread [12]. The group adjusted operating margin in the second quarter was 29.3%, with RIS at 35.3% and consulting at 20.5%, adjusted earnings per share of $2.96 up 9% year over year, and first-half adjusted earnings per share up 8% [3][4]. The company also stated that third-quarter fiduciary interest income would be about $95 million, adjusted corporate expense about $75 million and interest expense similar to the second quarter's $250 million, while pointedly noting that margin expansion would be larger in the fourth quarter than in the third [3].

An alternative reading is that front-loaded charges imply front-loaded savings, and that the cautious phrasing about the third quarter merely clarifies the quarterly cadence rather than conceding that expansion is difficult [3]. The way to judge is the year-over-year direction of the margin: as long as the third quarter still expands year over year, net savings are outrunning the loss of interest income. Concretely, watch whether the company reaffirms another year of margin expansion, whether fiduciary interest income lands near $95 million and whether its year-over-year decline narrows, whether adjusted corporate expense is held within about $75 million, and how cumulative Thrive charges are tracking against the roughly $500 million budget along with any revision to the charge or savings estimate [3][10]. The evidential boundaries need stating too: the company never discloses realised savings separately, so the judgment rests on the year-over-year move in the adjusted operating margin and is therefore indirect; restructuring charges sit outside the adjusted measure, so a cost overrun would not show up in this debate's primary metric; and because the third quarter is seasonally the smallest, a sequential decline is not evidence [10][12].

Risks and Falsifiers

The first risk is that the soft property catastrophe reinsurance market pushes Guy Carpenter, operating as Marsh Re from September 2026, into negative growth, and that the January 1, 2027 renewal season deepens it. Guy Carpenter generated $2.496 billion in FY2025, 9.2% of the group, and second-quarter 2026 revenue of $664 million with underlying revenue down 2%, with the company saying rate alone was worth roughly six percentage points of drag; the property catastrophe rate-on-line index, which measures premium per unit of cover, fell 16% year over year at mid-year, the steepest decline in the index's twenty-five-year history, and property is 50% of its global portfolio [3][7]. Because the first half accounts for roughly three quarters of Guy Carpenter's annual revenue, the third quarter has a small base and limited impact, and the real amplifier arrives in the first half of next year; the observation that would falsify this risk is property catastrophe rate declines narrowing to within 10% in the third quarter or at the January 1, 2027 renewal, or Guy Carpenter returning to positive underlying growth [3].

The second risk is that Greensill-related litigation and other legal matters continue to generate new charges, depressing GAAP profit and diverting cash. The company recorded $425 million of estimated liability and legal costs for that litigation in the first quarter of 2026, which cut GAAP operating income 12% for the quarter and left GAAP earnings per share of $2.36 against $3.29 adjusted; the company described the charge as its best estimate of the liability following court-supervised mediation, but the litigation continues [6][8]. The observation that would falsify this risk is the absence of further charges related to the case in subsequent quarters, or disclosure of a final settlement no larger than the amount already accrued [8].

The third risk is that the downcycle in commercial insurance rates runs longer and deeper than the company expects, cancelling out the volume growth won through new business. Marsh Risk generated $14.366 billion in FY2025, 53.2% of the group, and composite rates were already down 6% in the second quarter with global property down 12%, so the exposed line is the group's single largest revenue stream [3][7]. The observation that would falsify this risk is composite rate declines narrowing to within 4% in the third quarter, or Marsh Risk holding underlying growth at no less than 4% even as rate declines deepen [3].

The fourth risk is that retention pressure in the health business persists, leaving Mercer's growth dependent for the long run on a wealth business driven by capital markets. Mercer generated $6.190 billion in FY2025, 22.9% of the group, of which health was $2.284 billion, and health underlying growth had already fallen to 3% in the second quarter [3][7]. The observation that would falsify this risk is health underlying growth returning to 5% or better in the third quarter, or the company disclosing improved retention [3].

The fifth risk is that the sales slowdown in the Middle East spreads to other regions, cancelling out the incremental projects generated by demand for artificial-intelligence transformation. Marsh Management Consulting generated $3.604 billion in FY2025, 13.4% of the group, and the company has already guided the third quarter down from the 13% actually delivered in the second to mid-to-high single digits [3][7]. The observation that would falsify this risk is third-quarter underlying growth landing within or above the guided range while the company does not widen its description of the affected regions [3].

The sixth risk is that fiduciary interest income keeps falling with rates faster than Thrive delivers net savings, breaking a nineteenth consecutive year of margin expansion. Fiduciary interest income was $403 million in FY2025 against $497 million in FY2024, the company has guided the third quarter to roughly $95 million, and Thrive's entire annualised saving is only about $400 million spread over three years, so the exposed line is the group adjusted operating margin itself [3][7][10]. The observation that would falsify this risk is the third-quarter adjusted operating margin expanding year over year while the year-over-year decline in fiduciary interest income narrows [3][12].

What to Watch Next

• Growth in the core broking business during the soft market: Marsh Risk underlying growth was 4% in the second quarter of 2026, the US and Canada were at 4%, and the composite rate index was down 6% [3]. Watch whether the US and Canada hold 4% and whether rate declines deepen or narrow. Deepening rate declines alongside unchanged growth would leave acquisitions and middle-market mix as the more likely support; rate declines narrowing to within 4%, or growth holding at no less than 4% while rates fall further, would falsify the view that price is dragging growth down.
• Whether Mercer Health has genuinely slowed: health underlying growth was 3% in the second quarter against 6% in the first [3][6]. Watch whether it returns to 5% and how the company explains retention. A return to 5% or better confirms a single-quarter fluctuation; staying below 4% confirms a step down.
• The quality of demand in management consulting: underlying growth was 13% in the second quarter, with the third quarter guided to mid-to-high single digits [3]. Watch whether the result lands between 6% and 9% and whether Quotient still ranks first for growth. Landing within or above the guided range without a widening of the affected regions confirms the current reading; falling outside the range falsifies it.
• Whether Thrive savings actually land: the group adjusted operating margin was 29.3% in the second quarter, fiduciary interest income was $88 million and adjusted corporate expense was $67 million [3]. Watch the year-over-year direction of the margin, whether interest income lands near $95 million and whether corporate expense is held within $75 million. Year-over-year expansion confirms that net savings are outrunning the loss of interest income; year-over-year contraction falsifies it.

Conclusion

Marsh's growth is driven by three independent pricing mechanisms: broking commissions on insurance and reinsurance charged against premium, consulting and investment fees charged by project and against assets under management, and fiduciary interest income that floats with short-term rates [1][7]. The current financial position is solid but not comfortable: FY2025 revenue of $26.981 billion, operating income of $6.223 billion and free cash flow of $5.001 billion, with first-half 2026 adjusted earnings per share of $6.25, up 8%, and total debt of $22.382 billion against $1.700 billion of cash at the end of the second quarter [1][3][9]. What remains genuinely unresolved is the relationship between price and volume: the composite rate index has fallen steadily to negative 6% while Marsh Risk still grew 4% on an underlying basis, and the disclosures available do not yet distinguish whether that resilience comes from winning new business or from the support of acquisitions and middle-market mix [3].

Looking outside the company's own account, only one piece of qualifying independent commentary appeared in this period. Anthony Lee of StockStory, in a peer comparison published on August 26, 2026, noted that Marsh's second-quarter revenue of $7.40 billion, up 6.2% year over year, came in 1.8% ahead of market expectations yet still ranked as the slowest growth among the five insurance brokers in that group [11]. That judgment does not directly contradict the company's position: Marsh emphasises that it still delivered 5% underlying growth in a soft market, while the peer comparison supplies a relative coordinate showing that holding a growth rate and outgrowing peers are not the same achievement, and cautioning against treating an absolute growth rate as the only evidence of growth capability [3][11]. Because this is the only independent piece in the period, it offers a direction rather than a settled view, and it should be read as an outside interpretation rather than as fact or as a vote.

What would materially change the current understanding is a combination of operating and financial observations arriving together. If third-quarter Marsh Risk underlying growth is still 4% with the US and Canada holding at 4%, Mercer Health returns to 5%, management consulting lands inside the mid-to-high single-digit range, and the adjusted operating margin expands year over year while fiduciary interest income comes in near $95 million, then the path of trading scale for growth and cost reduction for margin is strengthened [3]. If instead rate declines deepen while Marsh Risk growth slips, health stays below 4%, management consulting falls outside the guided range, or the adjusted operating margin contracts year over year even as corporate expense rises to about $75 million, the current understanding weakens, and the direction of rates at Guy Carpenter's January 1, 2027 renewal season would amplify that pressure further [3]. Separately, whether Greensill-related litigation produces further charges will determine whether the gap between GAAP and adjusted profit persists or gradually closes [8].

Sources

[1] MRSH 10-K filed 2026-02-09 · 2026-02-09 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000062709&type=10-K&dateb=&owner=include&count=40

[2] MRSH earnings calendar updated 2026-09-15 · 2026-09-15 · earnings calendar

[3] MRSH Q2 2026 earnings call 2026-07-21 · 2026-07-21 · earnings-call · https://www.corporate.marsh.com/investors/reporting/quarterly-earnings.html

[4] MRSH 8-K filed 2026-07-21 (Q2 2026 results release) · 2026-07-21 · 8-K · https://www.sec.gov/Archives/edgar/data/0000062709/000006270926000193/mmc2q2026ex991newsrelease.htm

[5] MarketBeat, "Marsh & McLennan Companies (MRSH) Earnings Date and Reports 2026", retrieved 2026-09-15 · 2026-09-15 · MarketBeat · https://www.marketbeat.com/stocks/NYSE/MRSH/earnings/

[6] MRSH Q1 2026 earnings call 2026-04-16 · 2026-04-16 · earnings-call · https://www.corporate.marsh.com/investors/reporting/quarterly-earnings.html

[7] MRSH 10-K FY2025 revenue disaggregation table · 2026-02-09 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000062709&type=10-K&dateb=&owner=include&count=40

[8] MRSH 10-Q filed 2026-04-16 · 2026-04-16 · 10-Q · https://www.sec.gov/Archives/edgar/data/62709/000006270926000098/mrsh-20260331.htm

[9] MRSH 10-Q filed 2026-07-21 · 2026-07-21 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000062709&type=10-Q&dateb=&owner=include&count=40

[10] MRSH 10-K FY2025 Thrive program disclosure · 2026-02-09 · 10-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000062709&type=10-K&dateb=&owner=include&count=40

[11] StockStory, "Insurance Brokers Stocks Q2 Results: Benchmarking Marsh (NYSE:MRSH)", 2026-08-26 · 2026-08-26 · StockStory · https://stockstory.org/us/stocks/nyse/mrsh/news/earnings/insurance-brokers-stocks-q2-results-benchmarking-marsh-nysemrsh

[12] MRSH 10-Q filed 2026-07-21 restructuring note · 2026-07-21 · 10-Q · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000062709&type=10-Q&dateb=&owner=include&count=40